November 11, 2019

November 08, 2019

Subscribe to Latest Legal News and Analysis

FDA Issues Guidance on Use of Nanotechnology in Foods

The FDA recently issued a final guidance titled, “Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, including Food Ingredients that are Color Additives.” Although broader in scope, this guidance covers the use of nanotechnology in the manufacture of food ingredients, including color additives and food contact substances, i.e., packaging.

The basic message of this draft guidance is that food or packaging manufacturers who incorporate nanoscale ingredients into their products should be prepared to prove the resulting products are safe and appropriate tests were used to validate their safety. 

The guidance includes a review of the statutory and regulatory provisions governing food, food additives, and food contact substances. Food is considered adulterated if it includes a poisonous or deleterious substance or an unsafe food or color additive. In this context, “unsafe” means “not pre-approved by the FDA” unless the additive is generally recognized as safe (GRAS) by experts in the field. In general, color additives must also be pre-approved and there is no GRAS exception for color additives. The FDA’s approval of food products assumes that they are manufactured according to good manufacturing practices (GMP).

The guidance next describes the FDA’s process for assessing the safety of a food substance. In connection with the manufacturing process, the guidance notes that the manufacturing process can affect the identity of the food, the conditions of its use and the level of impurities it contains. The guidance then states: 

As with any other manufacturing technologies applied to food, nanotechnology and other emerging technologies may introduce issues that warrant additional or different evaluation during a safety assessment of a food substance. For example, so-called nano-engineered food substances can have significantly altered bioavailability and may, therefore, raise new safety issues that have not been seen in their traditionally manufactured counterparts. . . . When a food substance is manufactured to include a particle size distribution shifted more fully into the nanometer range, safety assessments should be based on data relevant to the nanometer version of the food substance. Where nano-engineered food substances have new properties, additional or different testing methods may be necessary to determine the safety of the food substance...Thus, as with any studies to support the safety of food substances, studies to establish the safety of food substances manufactured using nanotechnology should have been appropriately validated for these materials.

For food or color additives that have been approved by regulation, foods that have been identified as GRAS, or food contact substances that have been approved via a food contact notification to FDA, when there is a significant change to the manufacturing process, including the incorporation of nanoscale ingredients, the guidance recommends that the manufacturer take several steps:

  • Determine what changes have been made to the food substance, including its physicochemical structure and properties, purity and impurities 

  • Conduct a safety assessment for the food substance, including the factors set forth above, bioavailability, and toxicity 

  • Consider whether the substance is within a relevant regulation, GRAS determination, or food contact notification 

  • Consult with FDA about your conclusions 

  • Make a regulatory submission if warranted 

The guidance states the FDA’s view that it is unlikely nanotechnology applications in food substances will qualify as GRAS, so formal premarket review and approval will be necessary. 

In short, manufacturers of foods, food or color additives, and food contact substances who plan to incorporate nanoscale materials into their products will have to consider conducting safety testing of their products, according to tests that are validated for use with nanoscale materials, and obtain the FDA’s approval prior to marketing the products, or risk FDA enforcement action.

As always, it is important to recall the FDA guidance documents do not have the force of law, but rather simply represent the FDA’s current thinking on a topic. 

A pdf copy of the guidance is available here.

© 2019 BARNES & THORNBURG LLP

TRENDING LEGAL ANALYSIS


About this Author

Lynn Tyler Litigation lawyer Barnes Thornburg
Partner

Lynn Tyler helps innovative companies secure and preserve their market position and competitive advantage. He advises on FDA compliance, helps protect clients with patent infringement and validity opinions, helps and enforce intellectual property rights — which often must be asserted against imitators who seek to reap where they have not sown.

An accomplished advocate, Lynn litigates and represents clients involved in virtually all stages of the dispute resolution process, including pre-litigation counseling, alternative dispute resolution, formal and informal...

317-231-7392
Philip J. Faccenda, Jr., Barnes Thornburg Law Firm, South Bend, Corporate and Finance Law Attorney
Partner

Philip J. Faccenda, Jr. is the Managing Partner in the South Bend, Indiana office of Barnes & Thornburg LLP. He concentrates his practice in the areas of municipal finance, corporate transactions, and state and local taxation.

Mr. Faccenda regularly counsels and assists clients in financing transactions and general corporate matters, and he also assists clients in the acquisition and disposition of businesses. Mr. Faccenda serves as bond counsel in a variety of taxable and tax-exempt financings, including transactions for local government capital projects, non-profit facilities...

574-237-1148
Glenn Killoren, Barnes Thornburg Law Firm, Elkhart, Corporate and Real Estate Law Attorney
Partner

Glenn E. Killoren is a partner in Barnes & Thornburg LLP’s South Bend and Elkhart, Indiana offices, where he is a member of the firm’s Corporate Department and co-chairman of the firm's Nanotechnology Group.

Mr. Killoren concentrates his practice on general corporate matters including mergers and acquisitions, corporate finance, succession and tax planning, among other areas. He also has experience counseling clients on estate planning and commercial real estate matters, as well as considerable experience working in the recreational vehicle industry. He counsels RV manufacturers...

574-296-2549
Todd Vare IP lawyer Barnes Thornburg
Partner

Todd G. Vare is a partner resident in the Indianapolis office of Barnes & Thornburg LLP. Mr. Vare represents clients in the protection and enforcement of intellectual property rights in trial and appellate courts around the country, and was listed in the 2012 edition of Best Lawyers in America.

Mr. Vare has litigated patent disputes covering a wide variety of technologies, including herbicides/pesticides, dielectric fluids, genetics, pharmaceuticals, medical devices, telecommunications, microprocessor and integrated circuit designs, software programs...

317-231-7735